# Regulatory Role of miR-196a-5p in Angiogenesis-Related Markers in Endothelial Cells Exposed to Hypertensive Pregnancies

**Authors:** Aslah Nabilah Abdull Sukor, Nurul Iffah Mohd Isa, Nur Syakirah Othman, Azizah Ugusman, Mohd Faizal Ahmad, Nur Fariha Mohd Manzor, Shahidee Zainal Abidin, Amilia Aminuddin, Adila A. Hamid

PMC · DOI: 10.3390/ijms27042047 · 2026-02-22

## TL;DR

This study shows that miR-196a-5p affects angiogenesis-related genes in endothelial cells from pregnancies with hypertension, suggesting a potential role in future therapies.

## Contribution

The study identifies miR-196a-5p as a novel regulator of PDGFRA, VEGF, and bFGF in endothelial cells under hypertensive pregnancy conditions.

## Key findings

- miR-196a-5p is significantly upregulated in HUVEC exposed to HDP.
- Overexpression of miR-196a-5p downregulates PDGFRA, VEGF, and bFGF at the mRNA level.
- PDGFRA protein levels increase with miR-196a-5p overexpression and decrease with its inhibition.

## Abstract

Offspring of hypertensive disorders of pregnancies (HDP) exhibit early-life endothelial dysfunction and have an elevated susceptibility to hypertension during adulthood which is potentially mediated by microRNA (miRNA), a key regulator of gene expression. RNA sequencing showed that miR-196a-5p was significantly upregulated in HUVEC exposed to HDP and may regulate angiogenesis in endothelial cells. Therefore, this study aims to elucidate the role of miR-196a-5p in regulating angiogenesis in HUVEC exposed to HDP. miR-196a-5p expression was validated by stem-loop RT-qPCR. Predicted target genes were identified using four algorithms, miRWalk, miRDB, TargetScan, and DIANA-microT-CDS, focusing on angiogenesis-related genes. Protein expression was confirmed through ELISA. Stem-loop RT-qPCR showed that miR-196a-5p expression was significantly upregulated in HDP HUVEC. Bioinformatic analysis revealed that the PDGFRA gene, a key regulator for angiogenesis, was significantly enriched. Overexpression of miR-196a-5p significantly downregulated PDGFRA, VEGF, and bFGF in HDP HUVEC, whereas its suppression upregulated these genes significantly. The ELISA result confirmed the corresponding changes at the protein level. However, PDGFRA protein levels increased with miR-196a-5p overexpression and decreased with its inhibition. Collectively, the results indicate that miR-196a-5p may have a regulatory effect on PDGFRA, VEGF, and bFGF that is associated with angiogenesis, and the modifications could be beneficial in future epigenetic targeted therapy.

## Linked entities

- **Genes:** PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 5156], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422], FGF2 (fibroblast growth factor 2) [NCBI Gene 2247]

## Full-text entities

- **Genes:** IGF1R (insulin like growth factor 1 receptor) [NCBI Gene 3480] {aka CD221, IGFIR, IGFR, JTK13}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, MIR335 (microRNA 335) [NCBI Gene 442904] {aka MIRN335, hsa-mir-335, miRNA335, mir-335}, Mir196a2 (microRNA 196a-2) [NCBI Gene 100314048] {aka Mir196a, rno-mir-196a}, PGF (placental growth factor) [NCBI Gene 5228] {aka D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760}, AGO2 (argonaute RISC catalytic component 2) [NCBI Gene 27161] {aka CASC7, EIF2C2, LESKRES, LINC00980, PPD, Q10}, FLT1 (fms related receptor tyrosine kinase 1) [NCBI Gene 2321] {aka FLT, FLT-1, VEGFR-1, VEGFR1}, HOXA9 (homeobox A9) [NCBI Gene 3205] {aka ABD-B, HOX1, HOX1.7, HOX1G}, Anxa1 (annexin A1) [NCBI Gene 25380] {aka Anx1, p35}, CALM3 (calmodulin 3) [NCBI Gene 808] {aka CALM, CAM1, CAM2, CAMB, CPVT6, CaM}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, Bach1 (BACH transcriptional regulator 1) [NCBI Gene 304127], FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, DICER1 (dicer 1, ribonuclease III) [NCBI Gene 23405] {aka DCR1, Dicer, Dicer1e, GLOW, HERNA, K12H4.8-LIKE}, PBX1 (PBX homeobox 1) [NCBI Gene 5087] {aka CAKUHED}, ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) [NCBI Gene 25] {aka ABL, BCR-ABL, CHDSKM, JTK7, bcr/abl, c-ABL}, NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893] {aka ALPS4, CMNS, N-ras, NCMS, NRAS1, NS6}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, VWF (von Willebrand factor) [NCBI Gene 7450] {aka F8VWF, VWD}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MIR6753 (microRNA 6753) [NCBI Gene 102465451] {aka hsa-mir-6753}, MIR195 (microRNA 195) [NCBI Gene 406971] {aka MIRN195, miRNA195, mir-195}, MIR155 (microRNA 155) [NCBI Gene 406947] {aka MIRN155, miRNA155, mir-155}, ANXA1 (annexin A1) [NCBI Gene 301] {aka ANX1, LPC1}, MIR210 (microRNA 210) [NCBI Gene 406992] {aka MIRN210, mir-210}, CDKN1B (cyclin dependent kinase inhibitor 1B) [NCBI Gene 1027] {aka CDKN4, KIP1, MEN1B, MEN4, P27KIP1}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, MIR34C (microRNA 34c) [NCBI Gene 407042] {aka MIRN34C, miRNA34C, mir-34c}, MIR145 (microRNA 145) [NCBI Gene 406937] {aka MIRN145, miR-145, miRNA145}, IGF2BP1 (insulin like growth factor 2 mRNA binding protein 1) [NCBI Gene 10642] {aka CRD-BP, CRDBP, IMP-1, IMP1, VICKZ1, ZBP1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 5156] {aka CD140A, PDGFR-2, PDGFR2}, CALM1 (calmodulin 1) [NCBI Gene 801] {aka CALML2, CAM2, CAM3, CAMB, CAMC, CAMI}
- **Diseases:** injury to (MESH:D014947), inflammation (MESH:D007249), placental insufficiency (MESH:D010927), rheumatoid arthritis (MESH:D001172), Hypertensive (MESH:D006973), preterm birth (MESH:D047928), HDP (MESH:D046110), cardiovascular and cerebrovascular disease (MESH:D002318), eclampsia (MESH:D004461), endothelial dysfunction (MESH:D014652), Placental dysfunction (MESH:D010922), cancer (MESH:D009369), preeclampsia (MESH:D011225), hepatitis B virus (MESH:D006509), autoimmune disorders (MESH:D001327), gestational diabetes mellitus (MESH:D016640), ischemia (MESH:D007511), proteinuria (MESH:D011507), preeclamptic (MESH:C538543), systemic lupus erythematosus (MESH:D008180), pregnancy (MESH:D011254), endothelial (MESH:D005642), hypoxia (MESH:D000860), infectious diseases (MESH:D003141)
- **Chemicals:** ECM (-), penicillin (MESH:D010406), Lipofectamine (MESH:C086724), streptomycin (MESH:D013307), CO2 (MESH:D002245), SYBR  Green (MESH:C098022), biotin (MESH:D001710), nitric oxide (MESH:D009569), 4',6-diamidino-2-phenylindole (MESH:C007293)
- **Species:** Human immunodeficiency virus (species) [taxon 12721], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Moloney murine leukemia virus (no rank) [taxon 11801]
- **Cell lines:** HUVEC — Homo sapiens (Human), Finite cell line (CVCL_3722)

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940203/full.md

---
Source: https://tomesphere.com/paper/PMC12940203